Mount Sinai DoctorsTreats Adults
Accepting New Patients
Shambavi Richard, MD
Internal Medicine, Hematology-Oncology, Cancer (Oncology)
About Me
Shambavi Richard, MD, is Associate Professor of Medicine (Hematology and Medical Oncology) with the Center of Excellence for Multiple Myeloma. She sees multiple myeloma patients at the Ruttenberg Treatment Center at The Mount Sinai Hospital and also at The Blavatnik Family - Chelsea Medical Center. Dr. Richard applies a multi-disciplinary approach for each of her patients alongside her collaborative team members.
In practice for more than 17 years, Dr. Richard has extensive experience in transplantation for multiple myeloma. She is a principal investigator and is involved in several phase 1, phase 2, and first in human clinical trials in multiple myeloma with a focus on several novel therapies, including antibody, immunotherapy, and targeted therapy treatment approaches.
The Multiple Myeloma Program has played a pivotal role in the approval of several recent drugs that are now FDA approved for the treatment of multiple myeloma. Additionally, Dr. Richard leads a precursor clinic for multiple myeloma where she sees patients who have monoclonal gammopathies of uncertain significance (MGUS) and smoldering myeloma with a goal to prevent evolution to myeloma.
Language
Position
Hospital Affiliations
- Mount Sinai Morningside
- Mount Sinai Beth Israel
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai West
About Me
Shambavi Richard, MD, is Associate Professor of Medicine (Hematology and Medical Oncology) with the Center of Excellence for Multiple Myeloma. She sees multiple myeloma patients at the Ruttenberg Treatment Center at The Mount Sinai Hospital and also at The Blavatnik Family - Chelsea Medical Center. Dr. Richard applies a multi-disciplinary approach for each of her patients alongside her collaborative team members.
In practice for more than 17 years, Dr. Richard has extensive experience in transplantation for multiple myeloma. She is a principal investigator and is involved in several phase 1, phase 2, and first in human clinical trials in multiple myeloma with a focus on several novel therapies, including antibody, immunotherapy, and targeted therapy treatment approaches.
The Multiple Myeloma Program has played a pivotal role in the approval of several recent drugs that are now FDA approved for the treatment of multiple myeloma. Additionally, Dr. Richard leads a precursor clinic for multiple myeloma where she sees patients who have monoclonal gammopathies of uncertain significance (MGUS) and smoldering myeloma with a goal to prevent evolution to myeloma.
Language
Position
Hospital Affiliations
- Mount Sinai Morningside
- Mount Sinai Beth Israel
- Mount Sinai Brooklyn
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai West
